Table 1.

Characteristics of the included studies

Study	Published year	Study type	No. of cases	Endpoints	Treatment regimen	Radiation dose (Gy)	Endostatin usage	Total duration of endostatin
Jiang [16]	2012	Prospective cohort study	25	1-, 2-yr OS rate, 1-, 2-yr LCR, OS, ORR, AEs	ERT	60	15 mg/day IV for 7 days during the first week of RT	7 days× 1 cycles
Zhai [18]	2019	Single-arm prospective study	67	1-, 2-, 3-yr PFS/OS rate, PFS,OS, ORR, AEs	ECRT	60–66	7.5 mg/m2/day CIV for 5 days before the beginning of RT, and then repeated at week 2, 4, and 6 during RT	5 days× 4 cycles
Sun [21]	2016	Single-arm prospective study	19	ORR, PFS, OS, AEs	ECRT	60–66	7.5 mg/m2/day IV for 14 days per 3 weeks during RT	14 days× 2 cycles
Bao [22]	2015	Single-arm prospective study	48	OS, 1-, 2-, 3-yr PFS/OS rate and LCR, PFS, ORR, AEs	ECRT	60–66	7.5 mg/m2/day IV for 7 days before the beginning of RT, and then repeated at week 2, 4, and 6 during RT	7 day× 4 cycles
Tang [23]	2016	Single-arm retrospective study	78	PFS, OS, ORR	ECRT	60–66	7.5 mg/m2/day IV over 4 h per day for 7 days, or CIV for 5 days, at week 1, 3, 5 and 7, endostatin administrated 1 week prior to CRT	5/7 days× 4 cycles
Wen [24]	2009	Prospective cohort study	14	ORR, PFS, 1-yr OS rate	ERT	66–68	15 mg/day IV during the first three weeks of RT	21 days× 1 cycles
Chen [25]	2017	Prospective cohort study	20	ORR, PFS, OS, AEs	ERT	60–66	15 mg/day IV for 14 days per three weeks during RT	14 day×2 cycles

OS Overall survival, PFS Progression-free survival, ORR Objective response rate, LCR Local control rate, AEs Adverse events, ERT Endostatin combined with radiotherapy, ECRT Endostatin combined with concurrent chemoradiotherapy, yr Year, RT Radiotherapy, IV Intravenous injection, CIV Continuous intravenous pumping